Morningside was founded in 1986 by the Chan family of Hong Kong to make venture capital and private equity investments. The group is characterized by its long-term outlook in company-building and by its unwavering commitment to acting ethically. As pharmaceutical companies invest in expensive therapies often for diseases of very low incidence, Morningside does not shy away from developing affordable therapies for high-prevalence diseases such as tuberculosis, hepatitis B, asthma, autism and dementia. Long before COVID-19, Morningside has been investing in vaccines, the one medical intervention that has saved more lives in human history than any therapeutic has.